ArticleFrontiers in pharmacology2021
Integrated Analysis and Finding Reveal Anti-Liver Cancer Targets and Mechanisms of Pachyman (
Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- A Systematic Review on the Research Progress on Polysaccharides from Fungal Traditional Chinese Medicine.Molecules (Basel, Switzerland) · 2023Pooled it
- Efficacy and Safety of Fuzheng Jiedu Xiaoji Formula Combined with Conventional Western Therapy in Advanced HBV-HCC: A Single-Center, Randomized Controlled Trial.Chinese journal of integrative medicine · 2025Trial
- Process-Programmed Extraction-Structure-Activity Relationships (ESAR) in edible and medicinal mushroom polysaccharides: a mechanistic and application-oriented framework.Journal of advanced research · 2026Review
- Polysaccharides: Nature's Guardians of Freshness in Food Preservation.Molecules (Basel, Switzerland) · 2026Review
- Development and validation of a herb-related gene signature for prognosis prediction and therapeutic response assessment in breast cancer.Translational cancer research · 2026Article
- Gan-Jiang-Ling-Zhu Decoction Prevents Paigen's Diet-induced Lean Metabolic Dysfunction-associated Steatotic Liver Disease by Regulating Bile Acid Metabolism.Combinatorial chemistry & high throughput screening · 2026Article
- Huangqi fuling decoction inhibits the invasion and metastasis of gastric cancer via the TNF signaling pathway.Scientific reports · 2025Article
- The Role ofMolecules (Basel, Switzerland) · 2025Review
- Traditional Chinese Medicine for Liver Cancer Treatment: Network Pharmacology Research.Current topics in medicinal chemistry · 2025Review
- Identification of Anoikis-related potential biomarkers and therapeutic drugs in chronic thromboembolic pulmonary hypertension via bioinformatics analysis and in vitro experiment.Scientific reports · 2024Article
- Article
- Homotherapy for Heteropathy: A Molecular Mechanism of Poria Sini Decoction for Treatment of Liver Cancer and Chronic Heart Failure.Evidence-based complementary and alternative medicine : eCAM · 2024Article
- From petals to healing: consolidated network pharmacology and molecular docking investigations of the mechanisms underpinningFrontiers in pharmacology · 2024Article
- Preclinical study of pachyman inducing ferroptosis against ovarian cancer: Biological targets and underlying mechanisms.Food science & nutrition · 2023Article
- Article
- Article
- Quantification of Chemical Groups and Quantitative HPLC Fingerprint ofMolecules (Basel, Switzerland) · 2022Article
- Current Advancements in Antitumor Properties and Mechanisms of Medicinal Components in Edible Mushrooms.Nutrients · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This bioinformatics study aimed to characterize and certify crucial anti-cancer targets, functional processes, and molecular mechanisms of Pachyman in treating hepatocellular carcinoma (HCC) by using pharmacology network and molecular docking analyses, by experimental validation. The crucial anti-HCC targets of Pachyman, including ALB, VEGFA, TNF, CASP3, SRC, EGF, CXCR4, STAT3, HRAS, HSP90AA1, MMP9, BCL2L1, FGF2, and PTPRC, were identified. In addition, the correlative networks of all crucial biotargets of Pachyman in treating HCC were created accordingly. Functionally, these crucial genes were correlated using angiogenesis and neoplastic metastasis of HCC. Interestingly, the molecular docking findings indicated that ALB and VEGFA in HCC might be potent pharmacological targets of Pachyman. In experimental validation, the clinical samples of HCC showed reduced ALB protein expression and increased VEGFA protein level. Following Pachyman treatments
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.